Results 71 to 80 of about 55,357 (300)

Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019

Revista Información Científica, 2020
Introduction: no research records were found addressing the results of the application of botulinum toxin type A in patients with hemifacial spasm in Guantanamo province.
Talía Marzo-Ramírez, Tamara Mecías-Díaz   +1 more
doaj  

Challenging the Clostridium botulinum toxin type A (BoNT/A) with a selection of microorganisms by culture methods and extended storage of used vials to assess the loss of sterility [PDF]

, 2015
In 2002, botulinum toxin type A (BoNT/A) was approved by the US Food and Drug Administration (FDA) for cosmetic use. However, there may be procedural differences between the ways in which a clinician handles, applies and stores the product compared to ...
Crean, Stjohn, Dennison, Sarah Rachel, Morton, Leslie Hugh Glyn, Singhrao, Simarjit Kaur, Turner, Martin   +4 more
core  

MDSGene Systematic Review of Common Forms of Dominant Hereditary Spastic Paraplegia: Novel Insights

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder characterized by progressive spasticity and lower limb weakness. The most common forms of autosomal dominant HSP are caused by pathogenic variants in SPAST (SPG4 or HSP‐SPAST), ATL1 (SPG3A or HSP‐ATL1), and REEP1 (SPG31 or HSP‐REEP1).
Ce Kang, Rajasumi Rajalingam, Zachary Walls, Jana Huang, Christine Sun, Laura I. Rudaks, Dennis Yeow, Ashar Rasheed, Jenny W. Zhang, Moath Hamed, Marianthi Breza, Susen Schaake, Chetan Vekhande, Jason Massa, Robyn E. Massa, Aakash Shetty, Carolyn M. Sue, Franca Cambi, Oksana Suchowersky, Franca Vulinovic, Sonja Petkovic, Christine Klein, Katja Lohmann, Connie Marras, Kishore R. Kumar   +24 more
wiley   +1 more source

Immunogenicity of Botulinum Toxin Type A in Different Clinical and Cosmetic Treatment, a Literature Review

Life
Background: Botulinum toxin type A is widely utilized for both therapeutic and aesthetic purposes, yet concerns regarding its immunogenicity have raised issues related to treatment failure and adverse reactions.
Kar Wai Alvin Lee, Lisa Kwin Wah Chan, Angela Wai Kay Lee, Cheuk Hung Lee, Jovian Wan, Kyu-Ho Yi   +5 more
doaj   +1 more source

Cervical dystonia incidence and diagnostic delay in a multiethnic population. [PDF]

, 2020
BackgroundCurrent cervical dystonia (CD) incidence estimates are based on small numbers in relatively ethnically homogenous populations. The frequency and consequences of delayed CD diagnosis is poorly characterized.ObjectivesTo determine CD incidence ...
Albers, Kathleen, Bressman, Susan, Comella, Cynthia, Comyns, Kathleen, de Kleijn, Annelie, Fross, Robin, Goldman, Samuel, Gu, Zhuqin, Katz, Maya, Klingman, Jeffrey, LaHue, Sara C, Leimpeter, Amethyst, Lo, Raymond Y, Marras, Connie, Nelson, Lorene M, Ozelius, Laurie J, Saunders-Pullman, Rachel, Smit, Robin, Tanner, Caroline M, Van Den Eeden, Stephen K   +19 more
core   +2 more sources

The Pain in Dystonia Scale (PIDS)—Validation in Craniofacial and Upper Limb Dystonia

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Pain is one of the most disabling non‐motor symptoms in adult‐onset isolated dystonia (AOID). The Pain in Dystonia Scale (PIDS) was developed and validated in cervical dystonia. Its applicability to other focal subtypes remains unknown.
Veronica Bruno, Vittorio Velucci, Beatrice Achen, Marcello Mario Mascia, Antonella Muroni, Daniele Belvisi, Francesco Marchet, Laura Avanzino, Francesca Di Biasio, Roberto Erro, Cristiano Sorrentino, Lucio Marinelli, Flavio Villani, Antonio Pisani, Francesca Valentino, Angelo Fabio Gigante, Anna Castagna, Francesco Bono, Giovanni Cossu, Carlo Alberto Artusi, Carmen Terranova, Martina Petracca, Nicola Tambasco, Giovanni Defazio, Davide Martino   +24 more
wiley   +1 more source

Botulinum toxin type A for the management of glabellar rhytids

Clinical, Cosmetic and Investigational Dermatology, 2010
Anne Marie Tremaine, Jerry L McCulloughDepartment of Dermatology, University of California, Irvine, CA, USAAbstract: There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process.
Anne Marie Tremaine, Jerry L McCullough
doaj  

Single Application of A2 NTX, a Botulinum Toxin A2 Subunit, Prevents Chronic Pain Over Long Periods in Both Diabetic and Spinal Cord Injury–Induced Neuropathic Pain Models

Journal of Pharmacological Sciences, 2012
Botulinum toxin type A is a unique candidate for inhibition of pain transmission. In the present study we attempted to see the beneficial actions of A2 neurotoxin (NTX), an active subunit of botulinum toxin type A.
Lin Ma, Jun Nagai, Yuki Sekino, Yoshitaka Goto, Shinji Nakahira, Hiroshi Ueda   +5 more
doaj   +1 more source

BOTOX injection to treat strabismus after infant botulism type B infection

American Journal of Ophthalmology Case Reports, 2020
Purpose: The significance of botulinum toxin to ophthalmologists is twofold. Botulism, a medical emergency, frequently presents with ocular findings including blurred vision, diplopia, ptosis, and photophobia as a result of the neurotoxin produced by ...
Sarah G. Bonaffini, Victoria Cocozza, Jing Jin   +2 more
doaj   +1 more source

Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins. [PDF]

, 2020
Botulinum neurotoxin (BoNT) is one of the most acutely lethal toxins known to humans, and effective treatment for BoNT intoxication is urgently needed. Single-domain antibodies (VHH) have been examined as a countermeasure for BoNT because of their high ...
Jin, Rongsheng, Lam, Kwok-Ho, McNutt, Patrick M, Ondeck, Celinia, Perry, Kay, Shoemaker, Charles B, Tremblay, Jacqueline M, Vazquez-Cintron, Edwin, Webb, Robert P   +8 more
core